CAPR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Capricor Therapeutics Inc (CAPR) is not a strong buy for a beginner investor with a long-term strategy at this moment. While analysts maintain optimistic price targets and positive ratings, the lack of recent positive news, weak financial performance, and neutral trading sentiment suggest that this stock does not present an immediate buying opportunity. The technical indicators and options data also do not support a strong bullish case currently.
The MACD histogram is negative (-0.317) and contracting, indicating bearish momentum. RSI is neutral at 49.519, suggesting no clear overbought or oversold condition. Moving averages are converging, showing no strong trend. Support is at 28.605, and resistance is at 32.311. The stock is trading near its pivot level (30.458), indicating indecision.
The drug has first-in-class potential for treating Duchenne muscular dystrophy, which could lead to multi-billion-dollar revenue prospects. The company has sufficient cash ($318M) to fund operations through 2027.
The company's financial performance in Q4 2025 was weak, with revenue dropping to 0 (-100% YoY) and gross margin also at 0 (-100% YoY). While net income and EPS improved, they remain negative. Technical indicators are neutral to bearish, and the stock trend analysis predicts a likely decline in the next week (-2.4%) and month (-7.26%).
In Q4 2025, revenue dropped to 0 (-100% YoY), gross margin also fell to 0 (-100% YoY), while net income improved to -30.17M (+323.95% YoY) and EPS increased to -0.62 (+287.50% YoY). Despite improvements in net income and EPS, the overall financials remain weak.
Analysts are bullish, with multiple firms raising price targets (e.g., Roth Capital to $43, B. Riley to $63, Piper Sandler to $58). They cite confidence in FDA approval for Deramiocel and its potential for strong revenue growth. However, the stock's recent performance and lack of immediate catalysts make it less compelling for a beginner investor seeking long-term stability.
